RSV BRONCHIOLITIS: VALIDATION OF THE DIAGNOSIS IN HOSPITALIZATIONS

Mónica López-Lacort¹, Cintia Muñoz-Quiles¹, Alejandro Orrico-Sánchez¹, Javier Díez-Domingo¹ ¹Vaccine Research Department, FISABIO-Public Health, Valencia, Spain

To validate the reliability of the bronchiolitis cases due to Respiratory Syncytial Virus (RSV) recorded in the Minimum Basic Data Set (MBDS), by calculating the positive predictive value (PPV) using the Valencia Microbiological Network (RedMiVa) as the reference standard.

Methods

A retrospective population-based study using health databases of Valencia Region.



estimated **PPV** was:

Health databases of Valencia Region

Population: Children under 2 years of age born between 2008 and 2012 with an admission for RSV bronchiolitis. Period: 2008-2012.

Case definition: First admission for bronchiolitis (ICD-9 466.11) in first diagnostic position. (Mc Connochie definition)

PPV estimation: 20% of the hospitalizations do not have an associated test result, this missing information was estimated by multiple imputation. The imputation and PPV were assessed using a Bayesian model adjusted by age, year of admission and hospital as a random effect.

Positives -Omited -Imputation -Negatives

Conclusion

The PPV of bronchiolitis due to RSV was 94%. Only 6% of the diagnoses would be incorrect.







Results

Of the **3707 RSV** bronchiolitis hospitalizations, 96.6% occurred in children under one year of age. Among them, **20.3%** (n = 753) had no associated laboratory test, 4.3% (n = 160) had negative test result and 75.3% (n = 2790) had positive test result. According to the imputation model, the

93.7% CI (95%) (92.7-94.7)

	RedMIVA (Gold standard)		
MBDS	+ TEST	- TEST	MISSING
466.11	2790	160	753

Other strategies



Missing = Negative Results 75.3 % CI(95%)(73.9-76.7)

Missing = Positive Results 95.7 % CI(95%)(95-96.3)

Missing values omitted 94.6 % CI(95%)(93.7-95.4)

ÁREA DE INVESTIGACIÓN EN VACUNAS